• Technology  > 

R&D PILLARS.

Notch collaborates closely within the pillars of our organization to advance our technologies to the clinic.

At the core of the Notch platform is the Engineered Thymic Niche (ETN™), a proprietary technology platform that unlocks the ability to generate T cells and other immune cells from renewable stem cell lines. This provides developing hematopoietic cells the right signals at the right time to predictably direct their development. By mimicking the niche of the human thymus, precursor cells differentiate through a series of stable intermediate populations and emerge as fully functional immune cells. The process has the potential to greatly simplify manufacturing and to produce immune cells at scale without the use of animal components or feeder cell lines.

—

[click to enlarge]
Notch cell therapies

---

Preclinical Sciences.

Our Preclinical Sciences team is focused on developing a robust pipeline of next-generation cellular immunotherapies designed to offer transformational benefits over the existing standard of care. The company has in-licensed or is developing a suite of technologies that could enable enhanced tumor-antigen specificity, control stem cell division and differentiation, alter the tumor microenvironment, and prevent immune susceptibility.

Notch cell enhancements

“Our Seattle-based team is located in one of the foremost cell therapy immune-oncology centers in the world and is focused on driving our discoveries to the clinic to help patients.”

-

Chris Bond, PhD
Senior Vice President, Preclinical & Translational Sciences

 

Advanced Cell Manufacturing.

Our Advanced Cell Manufacturing team is developing clinical-grade starting materials for the world’s most innovative cell therapy products.

Notch is establishing itself as a thought leader in the production of proprietary, commercial-grade, gene-edited iPSCs that are designed to meet global regulatory requirements and are developing using sophisticated processes for differentiating the iPSCs into functional T cells.

“We are designing stem cells with the global market in mind and have recruited top thought leaders to develop iPSC-based products that can be safely delivered to patients.”

-

Emily Titus, PhD
Vice President, Process Sciences

 

Research and Bioengineering.

Our Research and Bioengineering teams work with our Advanced Cell Manufacturing and Product Development teams to ensure that we are continually innovating and improving our products and processes.

“Notch’s ETN technology allows for unprecedented control of Notch signaling. We leverage that that control to achieve scale and reproducibility of a complex T cell differentiation process.”

-

Steven Woodside, PhD
Senior Director, Engineering

 

Systems Biology.

Systems Biology at Notch encompasses genomic data science, mechanism-based dynamic modeling, and machine learning. Computation is an integral to part of research, engineering, and translational medicine, directed toward both continual process improvement and product development. We are forging an entirely new therapeutic modality—this requires creativity in how we employ and repurpose diverse computational approaches to interpret our data and make decisions.

“We are tackling big problems at Notch and generating correspondingly big datasets. We use mathematical models to integrate this data, extract biological insights, and inform decisions across the organization.”

-

Dan Kirouac, PhD
Director, Systems Biology